Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA3-17 Injection in Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
NCT07188610Phase 2
Key facts
- Status
- Recruiting
- Start
- Sep 2025
- Primary completion
- Oct 2026
- Countries
- 1
- Sponsor
- PersonGen BioTherapeutics
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Drugs
- PA3-17
- Conditions
- T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)
01
Overview
Phase 2, open-label, single-arm trial of PA3-17 in T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL), sponsored by PersonGen BioTherapeutics. Primary endpoint: Efficacy at 3 months. Started Sep 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
T cell injection targeting CD7 chimeric antigen receptor
Single arm receiving PA3-17 injection after lymphodepletion
03
Who it enrols
Adults with CD7-positive relapsed/refractory T-cell lymphoblastic leukemia/lymphoma, ECOG 0-1, life expectancy >= 3 months, adequate organ function, no prior CAR-T therapy, and no active infections or severe autoimmune diseases.
04
Endpoints
Primary
Efficacy
Beyond the preview
Go deeper on NCT07188610.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188610.